OncoSec Medical to Present at Two Events in February
February 03 2015 - 6:03AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
it will present at two high-profile scientific and investment
conferences in February.
BIO CEO & Investor Conference
Punit Dhillon, President and CEO, will present a corporate
overview at the 17th Annual BIO CEO & Investor Conference, on
February 9-10, 2015 in New York City, NY. The presentation is
scheduled to begin at 9:30 AM ET on Monday, February 9 in the Duke
of Windsor room.
At the time of the presentation, a live webcast will be
available via the following link:
http://www.veracast.com/webcasts/bio/ceoinvestor2015/43106259832.cfm
OncoSec recommends registering at least 10 minutes prior to the
start of the presentation to ensure timely access. After the
presentation, an archived version of the webcast will be available
for 90 days in the “Events” section of the OncoSec web page at
http://www.oncosec.com.
Each year, the BIO CEO & Investor Conference provides a
forum for institutional investors, industry analysts, and senior
biotechnology executives to shape the future investment landscape
of the biotechnology industry. The conference features
issue-oriented plenary sessions, educational sessions focused on
hot therapeutic areas and key business issues, company
presentations, one-on-one meetings, and networking opportunities.
For more information, visit:
https://www.bio.org/events/conferences/bio-ceo-investor-conference
Molecular Medicine Tri-Conference 2015
Robert H. Pierce, MD, Chief Scientific Officer, will present at
Cambridge Healthtech Institute’s 22nd International Molecular
Medicine Tri-Conference, on February 15-20, 2015 at Moscone North
Convention Center in San Francisco, CA. Dr. Pierce’s lecture,
“Translational Approaches for the Development of Intratumoral
Immunotherapies,” is scheduled to begin at 11:15 AM PT on Tuesday,
February 17.
The 22nd International Molecular Medicine Tri-Conference is the
industry's preeminent event on molecular medicine, focusing on drug
discovery, genomics, diagnostics and information technology.
Spanning six days this year, the Tri-Conference includes an
expanded program that includes six symposia, over 20 short courses,
and 17 conference programs. For more information, please visit:
http://www.triconference.com.
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response without the systemic toxicities associated
with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase 2 development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
OncoSec Medical Inc.Investor Relations:Jordyn Kopin,
855-662-6732investors@oncosec.comorMedia Relations:Mary Marolla,
855-662-6732media@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024